{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:09:17Z","timestamp":1792382957208,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.medcli.2018.10.029","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T17:00:35Z","timestamp":1546534835000},"page":"397-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["S\u00edndrome de lisis tumoral"],"prefix":"10.1016","volume":"152","author":[{"given":"Jose Manuel","family":"Calvo Villas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2018.10.029_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumor lysis syndrome: New therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0010","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2018.10.029_bib0015","first-page":"1700","article-title":"Actuary ureter closure after irradiation with x-rays for chronic leukemias","volume":"25","author":"Bedrna","year":"1929","journal-title":"Med Klin"},{"key":"10.1016\/j.medcli.2018.10.029_bib0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0002-9343(80)90286-7","article-title":"Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma","volume":"68","author":"Cohen","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.medcli.2018.10.029_bib0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.emc.2018.04.003","article-title":"Rapid fire: Tumor lysis syndrome","volume":"36","author":"Dubbs","year":"2018","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.medcli.2018.10.029_bib0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2007-976175","article-title":"Tumor lysis syndrome","volume":"33","author":"Tiu","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.medcli.2018.10.029_bib0035","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0040","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0045","doi-asserted-by":"crossref","unstructured":"Jones GL, Will A, Jackson GH, Webb NJ, Rule S; British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 2015;169:661-71.","DOI":"10.1111\/bjh.13403"},{"key":"10.1016\/j.medcli.2018.10.029_bib0050","first-page":"61","article-title":"Incidence and pathogenesis of tumor lysis syndrome","volume":"147","author":"Locatelli","year":"2005","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","article-title":"Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma","volume":"94","author":"Hande","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.medcli.2018.10.029_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries","volume":"44","author":"Annemans","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2018.10.029_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V120.21.238.238","article-title":"Incidence of treatment-related, laboratory and clinical tumor lysis syndrome","volume":"120","author":"Cairo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2018.10.029_bib0070","first-page":"273","article-title":"Tumor lysis syndrome","volume":"13","author":"Arrambide","year":"1993","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: A systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.medcli.2016.10.040","article-title":"Tumor lysis syndrome in solid tumors: Clinical characteristics and prognosis","volume":"148","author":"Caravaca-Font\u00e1n","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2018.10.029_bib0085","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.4081\/rt.2014.5389","article-title":"Tumor lysis syndrome in solid tumors: An up to date review of the literature","volume":"6","author":"Mirrakhimov","year":"2014","journal-title":"Rare Tumors"},{"key":"10.1016\/j.medcli.2018.10.029_bib0090","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clon.2006.09.005","article-title":"Tumour lysis syndrome in solid tumours","volume":"18","author":"Gemici","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.medcli.2018.10.029_bib0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2710.2011.01260.x","article-title":"A review of tumour lysis syndrome with targeted therapies and the role of rasburicase","volume":"36","author":"Bose","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.medcli.2018.10.029_bib0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences and treatment of tumor lysis syndrome","volume":"116","author":"Davidson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.medcli.2018.10.029_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.12327","article-title":"Tumor lysis syndrome: Current perspective","volume":"93","author":"Hochberg","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2018.10.029_bib0110","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/ndt\/gfp330","article-title":"A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome","volume":"24","author":"Shimada","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2018.10.029_bib0115","first-page":"322","article-title":"Metabolic emergencies in the cancer patient","volume":"27","author":"Flombaum","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0120","first-page":"77","article-title":"[Guideline for management of tumor lysis syndrome] Spanish","volume":"109","year":"2011","journal-title":"Arch Argent Pediatr"},{"key":"10.1016\/j.medcli.2018.10.029_bib0125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/S1807-59322009000500016","article-title":"Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome","volume":"64","author":"Soares","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.medcli.2018.10.029_bib0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/SCT.2005.n.008","article-title":"Optimizing management of tumor lysis syndrome in adults with hematologic malignancies","volume":"2","author":"Michallet","year":"2005","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.medcli.2018.10.029_bib0135","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3324\/haematol.13290","article-title":"Consensus conference on the management of tumor lysis syndrome","volume":"93","author":"Tosi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2018.10.029_bib0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: Identification of risk factors and development of a predictive model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.medcli.2018.10.029_bib0145","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.medin.2010.07.014","article-title":"S\u00edndrome de lisis tumoral en terapia intensiva: encare diagn\u00f3stico y terap\u00e9utico","volume":"35","author":"Burghi","year":"2011","journal-title":"Med Intensiva"},{"key":"10.1016\/j.medcli.2018.10.029_bib0150","first-page":"285","article-title":"Analysis of the British guidelines 2015 for the management of adult tumor lysis syndrome","volume":"26","author":"Vasseur","year":"2017","journal-title":"Reanimation."},{"key":"10.1016\/j.medcli.2018.10.029_bib0155","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.revmed.2016.08.021","article-title":"[Analysis of the 2015\u00a0British guidelines on the prevention and management of tumor lysis syndrome] French","volume":"38","author":"Dupr\u00e9","year":"2017","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.medcli.2018.10.029_bib0160","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/ndt\/gfv372","article-title":"Acute kidney injury in critically ill patients with haematological malignancies: Results of a multicentre cohort study from the Groupe de Recherche en R\u00e9animation Respiratoire en Onco-H\u00e9matologie","volume":"30","author":"Darmon","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.medcli.2018.10.029_bib0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190903456959","article-title":"Prognostic of acute renal injury in acute tumor lysis syndrome","volume":"51","author":"Darmon","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2018.10.029_bib0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2007.05.003","article-title":"Tumor lysis syndrome in ederly","volume":"64","author":"Pumo","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0175","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2005.04.004","article-title":"Metabolic emergencies","volume":"58","author":"Spinazz\u00e9","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0180","series-title":"Manual del M\u00e9dico Residente en Hematolog\u00eda y Hemoterapia","first-page":"381","author":"Burgaleta","year":"2014"},{"key":"10.1016\/j.medcli.2018.10.029_bib0185","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/10428190500404662","article-title":"A predictive model for the detection of tumor lysis syndrome during AML induction therapy","volume":"47","author":"Mato","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.medcli.2018.10.029_bib0190","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/OTT.S103864","article-title":"Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase","volume":"10","author":"Alakel","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.medcli.2018.10.029_bib0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.ackd.2013.07.001","article-title":"Tumor lysis syndrome: New challenges and recent advances","volume":"21","author":"Wilson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.medcli.2018.10.029_bib0200","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1172\/JCI108700","article-title":"Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy","volume":"59","author":"Conger","year":"1977","journal-title":"J Clin Invest"},{"key":"10.1016\/j.medcli.2018.10.029_bib0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00467-006-0287-z","article-title":"Acute renal failure from xanthine nephropathy during management of acute leukemia","volume":"22","author":"LaRosa","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0210","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO.2000.18.8.1758","article-title":"Allopurinol: Intravenous use for prevention and treatment of hyperuricemia","volume":"18","author":"Smalley","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0215","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s10147-016-0971-3","article-title":"Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: A phase iii, randomized, multi-center trial comparing febuxostat and allopurinol","volume":"21","author":"Tamura","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0220","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.11612","article-title":"Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study","volume":"98","author":"Bosly","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.medcli.2018.10.029_bib0225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7150\/ijms.4.83","article-title":"Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and gout","volume":"4","author":"Cammalleri","year":"2007","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.medcli.2018.10.029_bib0230","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2017-0505","article-title":"Tumor lysis syndrome in the 21st century: To recreate risk factors and prognosis?","volume":"23","author":"Vincent","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.medcli.2018.10.029_bib0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.ajkd.2013.02.378","article-title":"Rasburicase in tumor lysis syndrome of the adult: A systematic review and meta-analysis","volume":"62","author":"Lopez-Olivo","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.medcli.2018.10.029_bib0240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1130-6343(06)73953-8","article-title":"An\u00e1lisis y protocolizaci\u00f3n de la utilizaci\u00f3n de rasburicasa en pacientes con neoplasias hematol\u00f3gicas","volume":"30","author":"Llinares","year":"2006","journal-title":"Farm Hosp"},{"key":"10.1016\/j.medcli.2018.10.029_bib0245","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone: Results of a multicenter phase iii study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.clml.2016.11.003","article-title":"A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome","volume":"17","author":"Cairo","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.medcli.2018.10.029_bib0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08697.x","article-title":"The clinical management of tumour lysis syndrome in haematological malignancies: Review","volume":"154","author":"Will","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0009-8981(03)00166-9","article-title":"A review of clinical and laboratory findings and treatment of tumor lysis syndrome","volume":"333","author":"Yarpuzlu","year":"2003","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.medcli.2018.10.029_bib0265","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pbc.21478","article-title":"Sevelamer hydrochloride: A novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children","volume":"51","author":"Abdullah","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.medcli.2018.10.029_bib0270","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","article-title":"An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome","volume":"36","author":"Mughal","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.medcli.2018.10.029_bib0275","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03150312","article-title":"Onco-nephrology: Tumor lysis syndrome","volume":"7","author":"Wilson","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.medcli.2018.10.029_bib0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/cc4907","article-title":"Clinical review: Specific aspects of acute renal failure in cancer patients","volume":"10","author":"Darmon","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.medcli.2018.10.029_bib0285","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/nep.12806","article-title":"Impact of dialysis requirement on outcomes in tumor lysis syndrome","volume":"22","author":"Garimella","year":"2017","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.medcli.2018.10.029_bib0290","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1634\/theoncologist.2017-0147","article-title":"In-hospital outcomes of tumor lysis syndrome: A population-based study using the national inpatient sample","volume":"22","author":"Durani","year":"2017","journal-title":"Oncologist"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318307322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775318307322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:49:12Z","timestamp":1758419352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775318307322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0025775318307322"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2018.10.029","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"S\u00edndrome de lisis tumoral","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2018.10.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}